Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.63 |
| ▸ | ATR | Q13535 | 1/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | MERTK | Q12866 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16222300 | 0.87 | L3MBTL1 (0.53) | DRD2DRD4ATRUSP30DYRK1A | |
| SCHEMBL363917 | 0.87 | CARM1 (0.69) | KMT2ANPC1MEN1RAB9ASMN1; SMN2 | |
| SCHEMBL19464802 | 0.86 | DRD4 (0.60) | DRD2DRD4USP30KMT2ANPC1 | |
| SCHEMBL16219440 | 0.86 | DRD4 (0.60) | DRD2DRD4USP30DYRK1AKMT2A | |
| Hydrochloric Acid SCHEMBL18704553 | 0.86 | CARM1 (0.68) | KMT2ANPC1MEN1RAB9ASMN1; SMN2 | |
| SCHEMBL16222341 | 0.85 | ALDH1A1 (0.56) | ATRKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10210729 | 0.85 | USP30 (0.70) | DRD2DRD4USP30NPC1RAB9A | |
| SCHEMBL2980074 | 0.84 | PKM (0.68) | DRD2DRD4USP30KMT2ANPC1 | |
| SCHEMBL14980369 | 0.84 | DRD4 (0.56) | DRD2DRD4ATRUSP30DYRK1A | |
| SCHEMBL13959947 | 0.83 | NPC1 (0.72) | KMT2ANPC1MEN1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | DRD2 4861/4885DRD4 4574/4885ATR 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.